

# Review article: non-alcoholic fatty liver disease and osteoporosis – clinical and molecular crosstalk

Y. Yilmaz<sup>\*,†</sup>

<sup>\*</sup>Institute of Gastroenterology,  
Marmara University, Istanbul, Turkey.

<sup>†</sup>Department of Gastroenterology,  
School of Medicine, Marmara  
University, Istanbul, Turkey.

## Correspondence to:

Dr Y. Yilmaz, Marmara Universitesi,  
Gastroenteroloji Enstitüsü, P.K. 53,  
Basibuyuk, Maltepe, 34840, Istanbul,  
Turkey.

E-mail: dryusufyilmaz@gmail.com

## Publication data

Submitted 15 April 2012

First decision 21 May 2012

Resubmitted 24 May 2012

Accepted 5 June 2012

EV Pub Online 26 June 2012

*This uncommissioned review article was  
subject to full peer-review.*

## SUMMARY

### Background

Low bone mineral density (BMD) has been reported in both paediatric and adult patients with non-alcoholic fatty liver disease (NAFLD). The mechanisms behind the reduced BMD in NAFLD are still not completely understood.

### Aim

To provide a critical overview of the pathophysiological pathways linking NAFLD, reduced BMD and osteoporosis, with a special focus on the alterations of soluble mediators which could link fat accumulation in the liver with bone health. The MEDLINE database was searched by a combination of keywords: non-alcoholic fatty liver disease OR hepatic steatosis OR metabolic syndrome OR insulin resistance AND bone mineral density OR osteoporosis OR bone AND biomarkers OR serum marker.

### Results

Several factors that may influence bone mineralisation and the increased risk of osteoporosis in NAFLD can be discussed. These include the release of cytokines from the inflamed liver which may influence the bone micro-environment, vitamin D deficiency, and limited physical activity. Circulating markers of bone metabolism, including osteopontin, osteoprotegerin, osteocalcin and fetuin-A, have been found to be altered in patients with NAFLD.

### Conclusion

A better understanding of the mechanisms that link bone metabolism and the liver may open a new frontier to fight two highly prevalent conditions like NAFLD and osteoporosis.

*Aliment Pharmacol Ther* 2012; **36**: 345–352

## INTRODUCTION

The term non-alcoholic fatty liver disease (NAFLD) refers to any fatty infiltration of the liver that is not caused by significant alcohol abuse.<sup>1–8</sup> From an epidemiological standpoint, the prevalence of NAFLD is twice as high in men than in women (42% vs. 24% respectively), but – similar to that of osteoporosis – increases significantly among postmenopausal women.<sup>6</sup> In addition, in accordance with the observed epidemiological figures for osteoporosis, the prevalence of NAFLD increases with age, from less than 20% in people under the age of 20 to more than 40% in people aged >60 years or higher.<sup>6</sup>

The metabolic syndrome (MS) is universally considered as the key factor in the pathogenesis of NAFLD.<sup>9, 10</sup> Interestingly, low bone mineral density (BMD) has been recognised as a potential health problem in both men and women suffering from the MS,<sup>11–14</sup> of which NAFLD is the hepatic manifestation.<sup>9</sup> Moreover, preliminary evidence seems to suggest that NAFLD may be associated with an increased risk of osteoporotic fractures.<sup>15</sup> Although the mechanisms behind the reduced BMD in NAFLD are still not completely understood, several factors that may influence bone health and mineralisation in NAFLD can be discussed. These include the chronic low-grade inflammation itself, which causes the release of cytokines from the inflamed liver, vitamin D deficiency, and limited physical activity. Circulating markers of bone metabolism, including osteopontin, osteoprotegerin, osteocalcin and fetuin-A, have been found to be altered in patients with NAFLD.

In the present review, we provide a critical overview of the potential pathways linking NAFLD with a reduced BMD, with a special focus on biochemical alterations of circulating bone-regulating markers. Toward this aim, the MEDLINE database was searched by a combination of keywords: non-alcoholic fatty liver disease OR hepatic steatosis OR metabolic syndrome OR insulin resistance AND bone mineral density OR osteoporosis OR bone AND biomarkers OR serum marker. A better understanding of the mechanisms that link bone metabolism and the liver may open a new frontier to fight two highly prevalent conditions like NAFLD and osteoporosis.

## NAFLD AND ITS ASSOCIATION WITH BONE MINERAL DENSITY: EPIDEMIOLOGICAL EVIDENCE

Growing evidence suggests the presence of a complex interplay between the skeleton and numerous homeostatic processes, including energy balance, insulin resistance, obesity and the MS. Recent years have also

witnessed an increased awareness of the clinical and epidemiological association between NAFLD and bone health (both in terms of reduced BMD and an increased risk of osteoporosis); at present, such an association has been independently reported by at least four studies in both children and adults.<sup>16–19</sup> In a case-control study of 82 obese children and 30 normal-weight controls, Pirgon *et al.*<sup>16</sup> demonstrated a negative association between BMD and insulin resistance in obese adolescents both with and without NAFLD. Moreover, obese children with NAFLD had a lower BMD than their non-NAFLD counterparts. The authors concluded that NAFLD could exert a negative impact on BMD in obese adolescents, probably via an increased insulin resistance.<sup>16</sup> Campos *et al.*<sup>17</sup> enrolled 40 postpuberty obese adolescents who were divided into two subgroups according to the presence or absence of NAFLD diagnosis using ultrasonography. Following a weight loss therapy, the authors measured the changes in BMD using dual-energy X-ray absorptiometry (DEXA). The authors found a positive correlation between the changes in BMD and the changes in fat mass, whereas a negative association with the changes in insulin resistance and leptin was found.<sup>17</sup> An important study by Pardee *et al.*<sup>18</sup> demonstrated that obese children with NAFLD had significantly lower bone mineral density Z-scores than obese children without fatty liver. In addition, 45% of children with NAFLD had low BMD adjusted for age, compared to none of the children without NAFLD.<sup>18</sup> Recently, Moon and coworkers<sup>19</sup> have examined the association between BMD and NAFLD in 381 pre and postmenopausal women. Lumbar BMD was measured using DEXA, whereas NAFLD was screened by means of liver ultrasonography. The results indicated that the mean lumbar BMD was lower in subjects with NAFLD than those without NAFLD in postmenopausal women even after adjusting for the presence of the MS. The authors considered BMD as related to NAFLD *per se* (i.e. independently of the MS) in postmenopausal females, and suggested that postmenopausal women with NAFLD may have a greater risk of osteoporosis than those without.<sup>19</sup> Taken together, these results indicated that NAFLD is associated with poor bone health both in obese children and postmenopausal women. In addition, a more severe liver disease seems to be associated with lower bone mineralisation.<sup>19</sup> This evidence is intriguing and set the stage for longitudinal investigations of BMD changes over the course of fatty liver. Future studies should explore whether the presence of more severe liver histology (hepatocellular ballooning, necroinflammation and fibrosis) could be associated with

a poorer bone health, and whether this in turn relates to an increased risk of osteoporotic fractures.<sup>15</sup>

### DECREASED BMD IN NAFLD: PATHOGENETIC INSIGHTS

Although there is evidence that NAFLD could be related to a reduced BMD from a clinical standpoint,<sup>16–19</sup> the pathogenesis of decreased BMD in NAFLD is currently unclear. However, this link is likely multifactorial and may include one or more of the following mechanisms, that is the release of cytokines and other bone-influencing molecules from the inflamed liver, vitamin D deficiency and reduced physical activity. We will therefore provide an overview of the mechanistic correlations between fatty liver and the osseous system – first focusing on the molecules that communicate between the liver and the skeleton.

### RELEASE OF CYTOKINES AND OTHER BONE-INFLUENCING MOLECULES FROM THE INFLAMED LIVER

#### Tumour necrosis factor (TNF)- $\alpha$

The observation that low BMD is already present in patients with newly diagnosed NAFLD prior to any treatment<sup>16–19</sup> suggests that the inflammatory process itself may play a role in the pathogenesis of disturbed bone mineralisation in this patient group. One of the potential key contributors in both hepatic inflammation and the pathophysiology of bone loss is tumour necrosis factor (TNF)- $\alpha$ . An increase in circulating levels of TNF- $\alpha$  has been reported in NAFLD patients by several independent investigators.<sup>20–22</sup> Of note, evidence suggests that increased TNF- $\alpha$  levels are both involved in the stimulation of osteoclastogenesis and in the inhibition of the activation of osteoblasts from their progenitor cells.<sup>23</sup> Furthermore, TNF- $\alpha$  stimulates the expression of genes that amplify osteoclastogenesis (interleukin-6, macrophage colony-stimulating factor) but also inhibits those that are involved in bone formation (alkaline phosphatase, vitamin D receptor, parathyroid hormone receptor).<sup>24</sup> Importantly, an inverse association between TNF- $\alpha$  and vitamin D levels has been reported,<sup>25</sup> which could in turn affect skeletal metabolism.

#### Osteopontin

Osteopontin (OPN) is a T-helper 1 cytokine that enhances the viability and growth of liver progenitor cells by binding to its specific receptor CD44.<sup>26</sup> It acts as a profibrogenic cytokine and activates the hedgehog

signalling pathway in the liver, a molecular cascade which is increased in parallel with fibrosis stage in non-alcoholic steatohepatitis (NASH).<sup>27</sup> In addition, OPN exacerbates inflammation in several chronic inflammatory diseases,<sup>28</sup> including NAFLD. A role for OPN in the pathogenesis of hepatic inflammation has been hypothesised from its proinflammatory actions and its effects on macrophages.<sup>29</sup> In a seminal study, Lima-Cabello *et al.*<sup>30</sup> demonstrated that the OPN gene is abundantly expressed in the liver of patients with NAFLD and chronic hepatitis C. Using a transgenic mouse model, Syn *et al.*<sup>27</sup> reported that OPN directly promotes fibrosis progression in NASH. Consistent with its putative role in NAFLD, genetic OPN deficiency has been recently shown to protect from obesity-induced hepatic steatosis by downregulating hepatic triacylglycerol synthesis in the mice.<sup>31</sup> Interestingly, Chang *et al.*<sup>32</sup> have reported that same OPN-deficient mice are resistant to ovariectomy-induced osteoporosis. Taken together, this evidence suggests that OPN overexpression found in NAFLD may be associated with less resistance to postmenopausal osteoporosis. This would be in keeping with the results by Chang *et al.*<sup>33</sup> who showed that high serum OPN levels >14.7 ng/mL can be considered a significant risk factor for menopausal osteoporosis. OPN, hyperexpressed in NAFLD,<sup>27</sup> is known to exert a direct effect on the osseous system by acting as a noncollagenous bone matrix protein.<sup>34</sup> In addition, OPN is known to modulate both osteoblastic and osteoclastic functions by inhibiting mineral crystal growth both *in vivo* and *in vitro*.<sup>35</sup> Taken together, these results suggest that OPN may have a role as a shared cytokine in the pathogenesis of NAFLD and osteoporosis.

#### Osteoprotegerin

Osteoprotegerin (OPG), a member of the TNF-receptor superfamily is a decoy receptor for the receptor activator for nuclear factor- $\kappa$ B (RANK) ligand and TNF-related apoptosis-inducing ligand.<sup>36, 37</sup> OPG is not only one of the major players in the balance between bone formation and bone resorption, but it also has important metabolic effects. In this regard, evidence suggests that obesity and insulin resistance are associated with reduced OPG concentrations.<sup>38</sup> In addition, serum OPG levels have been associated with several components of the MS in apparently healthy women.<sup>39</sup> In a pilot study, we have shown that concentrations of OPG are significantly lower in patients with definite NASH and borderline NASH compared with healthy individuals.<sup>40</sup> The area under the ROC curve for distinguishing between steatohepatitis

(definite NASH plus borderline NASH) from healthy controls using OPG was 0.82 in our sample.<sup>40</sup> Although the potential usefulness of reduced serum OPG concentrations for identifying patients with the most severe forms of NAFLD needs to be corroborated by independent studies, these preliminary data could prompt further research on the role played by OPG in the crosstalk between the NAFLD spectrum and the bone. In the skeletal system, OPG exerts osteoprotective effects by inhibiting osteoclast differentiation and activation and promoting osteoclast apoptosis.<sup>37</sup> Nevertheless, in relation to bone disease in the clinical setting, the association between OPG, bone density and fragility fractures remains controversial. In men, increased OPG levels have been associated with higher BMD of the lumbar spine,<sup>41, 42</sup> whereas other studies found a negative correlation<sup>43, 44</sup> or no correlation at all.<sup>45</sup> In women, both low<sup>46</sup> and high<sup>47</sup> OPG levels have been associated with vertebral fractures. Given these discrepant findings, future studies should clarify the relationship between serum OPG and BMD in NAFLD patients and to evaluate the role of OPG in bone status in this group of patients.

### Osteocalcin

Osteocalcin is a 49-amino acid bone matrix noncollagen protein expressed mainly by osteoblasts. It acts as a specific marker of bone formation and it is involved in calcium homeostasis.<sup>48</sup> Recently, osteocalcin has been recognised as a bone-derived hormone to regulate energy metabolism.<sup>48, 49</sup> Osteocalcin<sup>-/-</sup> knockout mice exhibits glucose intolerance, increased fat mass, insulin resistance, decreased expression of insulin target genes in liver and muscle and decreased adiponectin gene expression in the adipose tissue.<sup>50</sup> In contrast, administration of recombinant osteocalcin increases insulin secretion, decreased blood glycemia and contrasts the development of obesity in experimental studies.<sup>51</sup> In the clinical setting of chronic liver diseases, a pilot study reported decreased serum OCN levels in patients with primary biliary cirrhosis and in those with chronic alcoholic liver disease.<sup>52</sup> In a study of 28 obese patients, Fernández-Real *et al.*<sup>53</sup> have shown that circulating OCN concentrations are negatively associated with blood markers of liver injury and liver disease, including alanine transaminase (ALT) and aspartate transaminase (AST). In addition, the changes in ALT levels following weight loss in obese individuals were linearly associated with changes in OCN concentrations.<sup>53</sup> Recently, we found that patients with biopsy-proven NAFLD have significant reductions

in serum OCN concentrations (vs. matched controls) which were weakly, but significantly associated with the extent of hepatocyte ballooning, independent of insulin resistance and the MS.<sup>54</sup> In studies of bone metabolism, serum OCN levels have emerged as a sensitive marker of bone production<sup>55</sup>; of note, reduced OCN concentrations have been associated with postmenopausal osteoporosis.<sup>56</sup> Therefore, it is feasible that reduced OCN observed in patients with NAFLD could be one of the potential links between the presence of hepatic steatosis and a reduced BMD.

### Fetuin-A

Fetuin-A, also known as alpha-2-HS (Heremans-Schmid) glycoprotein, is produced in the liver and can be found in relatively high concentrations in human serum.<sup>57</sup> Fetuin-A is involved in the molecular mechanisms of insulin resistance by inhibiting the insulin receptor tyrosine kinase in skeletal muscle and hepatocytes, ultimately resulting in insulin resistance in these target tissues.<sup>57</sup> The fetuin-A null mice are insulin-sensitive and resistant to weight gain following a high fat diet.<sup>58</sup> In humans, higher fetuin-A levels associate with obesity and insulin resistance in the general population and are independently associated with the MS and its components.<sup>59, 60</sup> Moreover, high fetuin-A levels also associate with NAFLD and short-term diet and exercise interventions result in declines in serum fetuin-A levels which parallel the improvement in NAFLD and the reduction in body weight.<sup>61-63</sup> Fetuin-A has also recently emerged as a mineral carrier protein and a systemic inhibitor of pathological mineralisation.<sup>64</sup> In this regard, several lines of evidence have also indicated that circulating fetuin-A levels could be associated with markers of bone turnover.<sup>65, 66</sup> Animal studies have shown that the fetuin-A null mouse displays growth plate defects, increased bone formation with age and enhanced cytokine-dependent osteogenesis.<sup>67</sup> In addition, Chailurkit *et al.*<sup>66</sup> showed that circulating fetuin-A is related to bone mass and bone resorption markers in elderly women. It can be therefore hypothesised that alterations in circulating fetuin-A levels can lead to deficits in bone mineral density in subjects with NAFLD; whether these changes are of clinical significance and possibly influencing fracture risk over the lifetime in these subjects deserve further investigation.

### VITAMIN D, THE OSSEOUS SYSTEM AND NAFLD

Besides its role in calcium and bone metabolism, vitamin D exerts multiple pleiotropic effects in many tissues (e.g.

antiproliferative, prodifferentiative and immunomodulatory actions).<sup>68</sup> In addition, vitamin D receptors are present in several cell types, including pancreatic beta cells.<sup>69</sup> The main source of vitamin D is endogenous generation of cholecalciferol (vitamin D3) from 7-dehydrocholesterol in skin keratinocytes through exposure to medium-wavelength ultraviolet light (UVB) from the sun.<sup>70</sup> Some vitamin D also derives from dietary intake and vitamin D supplements. Vitamin D is either stored in adipose tissue or converted to 25-hydroxyvitamin D (25(OH)D or calcidiol) in the liver.<sup>68</sup> The serum concentration of 25(OH)D, the major circulating form of vitamin D, is considered to reflect the total production of vitamin D from both endogenous and exogenous sources and constitutes the best clinical measure of vitamin D stores.<sup>68</sup> The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D or calcitriol), is primarily generated in the kidney from 25(OH)D. 1,25(OH)<sub>2</sub>D functions as a steroid hormone regulating the transcription of numerous genes.<sup>71</sup> A number of clinical studies have shown that vitamin D deficiency can play a role in a number of different metabolic derangements, including type-1 and type-2 diabetes, obesity, dyslipidemia, hypertension and the MS.<sup>72–74</sup> Recent years have also witnessed a significant scientific interest into the potential role played by vitamin D in liver pathophysiology and NAFLD. An experimental study by Nakano *et al.*<sup>75</sup> showed that phototherapy may be a good complementary therapy for NASH because of its regulation on vitamin D3. Roth *et al.*<sup>76</sup> recently reported that vitamin D deficiency in obese rats exacerbates NAFLD and increases the hepatic expression of genes involved in inflammatory pathways. With regard to clinical studies, Targher *et al.*<sup>77</sup> reported that NAFLD patients have a

marked reduction in serum 25(OH)D levels compared with controls; this decrease was closely associated with the histopathological features of NAFLD. These results were independently confirmed by Barchetta *et al.*,<sup>78</sup> who showed that low 25(OH)D levels were associated with the presence of ultrasound-diagnosed NAFLD independently from metabolic syndrome, diabetes and insulin resistance. However, Katz *et al.*<sup>79</sup> did not confirm an independent association between vitamin D status and suspected NAFLD after adjusting for obesity in adolescents. Future studies are needed to clarify whether the vitamin D status should be routinely checked in NAFLD patients and deficiency corrected if present. In addition, the consequences of addressing hypovitaminosis D on both liver histology and bone health in this group of patients need to be determined in longitudinal clinical trials.

#### LIMITED PHYSICAL ACTIVITY IN THE LINK BETWEEN NAFLD AND REDUCED BMD

Physical activity is an important predictor of health in older adults, although the mechanisms remain poorly understood. Physical activity is currently considered as a cornerstone for the prevention of both NAFLD<sup>80</sup> and osteoporosis.<sup>81</sup> Various training studies have shown that exercise reduces levels of visceral adiposity in the absence of weight loss, which might be a key mechanism in protection from the MS and NAFLD.<sup>82</sup> Therefore, lifestyle modifications with weight loss and exercise are regarded as first line treatments in patients with hepatic fat accumulation. Besides its positive effects on the cardiometabolic function, exercise is thought to strengthen skeletal bones through gravitational forces or muscle pull producing strains within the skeleton.<sup>83</sup> If a strain is

**Table 1 | Soluble mediators involved in the link between NAFLD and osteoporosis**

Molecule	Purported role in NAFLD	Purported role in osteoporosis	Change in NAFLD	References
Tumour necrosis factor (TNF)- $\alpha$	Key mediator of hepatic inflammation	Amplifies osteoclastogenesis and inhibits bone formation	↑	[21, 22]
Osteopontin	Molecular mediator of hepatic inflammation and fibrosis	Modulates both osteoblastic and osteoclastic functions by inhibiting mineral crystal growth	↑	[30]
Osteoprotegerin	Reduced levels of this molecule are associated with obesity and insulin resistance	Major player in the balance between bone formation and bone resorption	↓	[40]
Osteocalcin	Increases insulin secretion	Marker of bone production	↓	[52–54]
Fetuin-A	Inhibits the insulin receptor tyrosine kinase and is involved in insulin resistance	Mineral carrier protein and systemic inhibitor of pathological mineralisation	↑	[61–63]

detected as greater than the optimum strain, then bone formation will occur. There is strong evidence that aerobic and strength/resistance activities are effective forms of weight-bearing exercise to minimise bone loss and osteoporosis.<sup>83</sup> Consistent data from randomised controlled trials show that exercise training programmes can prevent or reverse almost 1% of bone loss per year in both pre and postmenopausal women.<sup>84</sup> These observations point to the direction that a reduction in physical activity could lead both at a decrease in BMD at one hand, but may also metabolically affect tissues, such as the liver, thus resulting in insulin resistance and ectopic fat accumulation.

## CONCLUSIONS

Besides the well-described links between inflammatory bowel diseases, coeliac disease and osteoporosis,<sup>85–87</sup>

recent studies have also suggested that NAFLD may act as a risk factor for a reduced BMD in both children and adult populations. In this review, various pathophysiological mechanisms – including a variety of soluble mediators (Table 1) – that can play a role in the link between NAFLD and the osseous system have been discussed. The list of identified mechanisms is already long and still growing, although future research should aim to confirm the physiological relevance of NAFLD in relation to the risk of osteoporosis-related bone fractures. A better understanding of the mechanisms that link bone metabolism and the liver may open a new frontier to fight two highly prevalent conditions like NAFLD and osteoporosis.

## ACKNOWLEDGEMENT

*Declaration of personal and funding interests:* None.

## REFERENCES

1. Law K, Brunt EM. Nonalcoholic fatty liver disease. *Clin Liver Dis* 2010; **14**: 591–604.
2. Wlazlo N, van Greevenbroek MM, Ferreira I, Bravenboer B, Stehouwer CD. The diagnosis of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2012; **35**: 204–5.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274–85.
4. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. *World J Gastroenterol* 2010; **16**: 5286–96.
5. Browning JD, Szczepaniak LS, Dobbins R, *et al.* Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387–95.
6. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. *Ann Epidemiol* 2007; **17**: 863–9.
7. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008; **28**: 13–24.
8. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008; **28**: 503–22.
9. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. *Proc Nutr Soc* 2010; **69**: 211–20.
10. Fabbri E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010; **51**: 679–89.
11. Kim HY, Choe JW, Kim HK, *et al.* Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. *Calcif Tissue Int* 2010; **86**: 350–8.
12. Yaturu S, Humphrey S, Landry C, *et al.* Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. *Med Sci Monit* 2009; **15**: CR5–9.
13. Szulc P, Varennes A, Delmas PD, *et al.* Men with metabolic syndrome have lower bone mineral density but lower fracture risk—the MINOS study. *J Bone Miner Res* 2010; **25**: 1446–54.
14. Jeon YK, Lee JG, Kim SS, *et al.* Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. *Endocr J* 2011; **58**: 87–93.
15. Li M, Xu Y, Xu M, *et al.* Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese. *J Clin Endocrinol Metab* 2012; **97**: 2033–8.
16. Pirgon O, Bilgin H, Tolu I, *et al.* Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. *Clin Endocrinol (Oxf)* 2011; **75**: 189–95.
17. Campos RM, de Piano A, da Silva PL, *et al.* The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. *Endocrine* 2012; doi:10.1007/s12020-012-9613-3.
18. Pardee PE, Dunn W, Schwimmer JB. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. *Aliment Pharmacol Ther* 2012; **35**: 248–54.
19. Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. *Endocrine* 2012; doi:10.1007/s12020-012-9639-6.
20. Aigner E, Theurl I, Theurl M, *et al.* Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. *Am J Clin Nutr* 2008; **87**: 1374–83.
21. Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF- $\alpha$  levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. *Am J Clin Pathol* 2007; **127**: 954–60.
22. Chu CJ, Lu RH, Wang SS, *et al.* Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor- $\alpha$ . *Hepatogastroenterology* 2007; **54**: 2099–102.

23. Zou W, Hakim I, Tsochoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor- $\alpha$  mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. *J Cell Biochem* 2001; **83**: 70–83.
24. Nanes MS. Tumor necrosis factor- $\alpha$ : molecular and cellular mechanisms in skeletal pathology. *Gene* 2003; **321**: 1–15.
25. Peterson CA, Heffernan ME. Serum tumor necrosis factor- $\alpha$  concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm (Lond)* 2008; **5**: 10.
26. Philips GM, Chan IS, Swiderska M, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. *PLoS One* 2011; **6**: e23943.
27. Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology* 2011; **53**: 106–15.
28. Morimoto J, Kon S, Matsui Y, Uede T. Osteopontin; as a target molecule for the treatment of inflammatory diseases. *Curr Drug Targets* 2010; **11**: 494–505.
29. Machado MV, Cortez-Pinto H. Osteopontin: a missing link between hedgehog signaling and fibrosis in nonalcoholic steatohepatitis. *Hepatology* 2011; **53**: 382–4.
30. Lima-Cabello E, García-Mediavilla MV, Miqulena-Colina ME, et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. *Clin Sci (Lond)* 2011; **120**: 239–50.
31. Kiefer FW, Neschen S, Pfau B, et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. *Diabetologia* 2011; **54**: 2132–42.
32. Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. *Osteoporos Int* 2011; **22**: 577–85.
33. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. *Osteoporos Int* 2010; **21**: 1401–9.
34. Fujisawa R, Tamura M. Acidic bone matrix proteins and their roles in calcification. *Front Biosci* 2012; **17**: 1891–903.
35. Ishijima M, Rittling SR, Yamashita T, et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. *J Exp Med* 2001; **193**: 399–404.
36. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. *J Endocrinol Invest* 2009; **32**(Suppl. 4): 6–9.
37. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). *Eur J Cell Biol* 2009; **88**: 1–17.
38. Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C. Osteoprotegerin and diabetes-associated pathologies. *Curr Mol Med* 2011; **11**: 401–16.
39. Oh ES, Rhee EJ, Oh KW, et al. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. *Metabolism* 2005; **54**: 49–54.
40. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. *Scand J Clin Lab Invest* 2010; **70**: 541–6.
41. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. *Osteoporos Int* 2005; **16**: 417–23.
42. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. *Eur J Endocrinol* 2007; **156**: 555–62.
43. Khosla S, Arrighi HM, Melton LJ 3rd, et al. Correlates of osteoprotegerin levels in women and men. *Osteoporos Int* 2002; **13**: 394–9.
44. Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. *Clin Endocrinol (Oxf)* 2005; **62**: 92–8.
45. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. *J Clin Endocrinol Metab* 2001; **86**: 3162–5.
46. Mezquita-Raya P, de la Higuera M, Garcia DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. *Osteoporos Int* 2005; **16**: 1368–74.
47. Jørgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. *J Bone Miner Metab* 2004; **22**: 132–8.
48. Ducy P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. *Diabetologia* 2011; **54**: 1291–7.
49. Fernández-Real JM, Ricart W. Osteocalcin: a new link between bone and energy metabolism. Some evolutionary clues. *Curr Opin Clin Nutr Metab Care* 2011; **14**: 360–6.
50. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. *Cell* 2007; **130**: 456–69.
51. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. *Proc Natl Acad Sci U S A* 2008; **105**: 5266–70.
52. Szalay F, Lakatos P, Németh J, et al. Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases. *Orv Hetil* 1991; **132**: 1301–5.
53. Fernández-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. *Osteoporos Int* 2010; **21**: 2101–7.
54. Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. *Scand J Clin Lab Invest* 2011; **71**: 631–6.
55. Patterson-Buckendahl P. Osteocalcin is a stress-responsive neuropeptide. *Endocr Regul* 2011; **45**: 99–110.
56. Pietschmann P, Resch H, Krexner E, Woloszczuk W, Willvonseder R. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis. *Acta Med Austriaca* 1991; **18**: 114–6.
57. Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. *Recent Pat Endocr Metab Immune Drug Discov* 2011; **5**: 124–46.
58. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. *Biochem Biophys Res Commun* 2006; **350**: 437–43.

59. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. *Circulation* 2006; **113**: 1760–7.
60. Xu Y, Xu M, Bi Y, *et al.* Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. *Atherosclerosis* 2011; **216**: 180–6.
61. Haukeland JW, Dahl TB, Yndestad A, *et al.* Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. *Eur J Endocrinol* 2012; **166**: 503–10.
62. Yilmaz Y, Yonal O, Kurt R, *et al.* Serum fetuin A/ $\alpha$ 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. *Ann Clin Biochem* 2010; **47**: 549–53.
63. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. *J Clin Endocrinol Metab* 2008; **93**: 4479–85.
64. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. *Circ Res* 2011; **108**: 1494–509.
65. Rasul S, Ilhan A, Reiter MH, *et al.* Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. *Clin Endocrinol (Oxf)* 2012; **76**: 499–505.
66. Chailurkit L, Kruavit A, Rajatanavin R, Ongphiphadhanakul B. The relationship of fetuin-A and lactoferrin with bone mass in elderly women. *Osteoporos Int* 2011; **22**: 2159–64.
67. Szweras M, Liu D, Partridge EA, *et al.* alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. *J Biol Chem* 2002; **277**: 19991–7.
68. Lips P. Vitamin D Physiology. *Prog Biophys Mol Biol* 2006; **92**: 4–8.
69. Lee S, Clark SA, Gill RK, Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. *Endocrinology* 1994; **134**: 1602–10.
70. Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. *J Bone Miner Res* 2007; **22**(Suppl. 2): V28–33.
71. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. *Am J Clin Nutr* 2008; **88**: 491S–499S.
72. Devaraj S, Jialal G, Cook T, Siegel D, Jialal I. Low vitamin D levels in Northern American adults with the metabolic syndrome. *Horm Metab Res* 2011; **43**: 72–4.
73. Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. *Diabetes Care* 2010; **33**: 1373–5.
74. Teegarden D, Donkin SS. Vitamin D: emerging new roles in insulin sensitivity. *Nutr Res Rev* 2009; **22**: 82–92.
75. Nakano T, Cheng YF, Lai CY, *et al.* Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. *J Hepatol* 2011; **55**: 415–25.
76. Roth CL, Elfers CT, Figlewicz DP, *et al.* Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. *Hepatology* 2012; **55**: 1103–11.
77. Targher G, Bertolini L, Scala L, *et al.* Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutr Metab Cardiovasc Dis* 2007; **17**: 517–24.
78. Barchetta I, Angelico F, Del Ben M, *et al.* Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med* 2011; **9**: 85.
79. Katz K, Brar PC, Parekh N, Liu YH, Weitzman M. Suspected nonalcoholic fatty liver disease is not associated with vitamin D status in adolescents after adjustment for obesity. *J Obes* 2010; **2010**: 496829.
80. Zelber-Sagi S, Ratzin V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. *World J Gastroenterol* 2011; **17**: 3377–89.
81. Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. *Sports Med* 2005; **35**: 779–830.
82. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. *Cochrane Database Syst Rev* 2011; **6**: CD003619.
83. Maimoun L, Sultan C. Effects of physical activity on bone remodeling. *Metabolism* 2011; **60**: 373–88.
84. Hamilton CJ, Swan VJ, Jamal SA. The effects of exercise and physical activity participation on bone mass and geometry in postmenopausal women: a systematic review of pQCT studies. *Osteoporos Int* 2010; **21**: 11–23.
85. Ludvigsson JF, Michaelsson K, Ekblom A, Montgomery SM. Coeliac disease and the risk of fractures - a general population-based cohort study. *Aliment Pharmacol Ther* 2007; **25**: 273–85.
86. Schulte CM. Review article: bone disease in inflammatory bowel disease. *Aliment Pharmacol Ther* 2004; **20**(Suppl. 4): 43–9.
87. Bernstein CN, Leslie WD. Review article: osteoporosis and inflammatory bowel disease. *Aliment Pharmacol Ther* 2004; **19**: 941–52.